AMOEBA (EPA:ALMIB) - Amoéba: AMOEBA BIOCONTROL SOLUTIONS TESTED BY EVERGREEN GARDEN CARE FOR HOME GARDEN APPLICATIONS

Transparency directive : regulatory news

14/04/2020 17:45

PRESS RELEASE

  AMOEBA BIOCONTROL SOLUTIONS TESTED BY EVERGREEN GARDEN CARE FOR HOME GARDEN
                               APPLICATIONS

Chassieu (France), april 14 2020 - AMOEBA (FR0011051598 - AMEBA), producer of a
biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
announces the signature of a Material Transfer Agreement (MTA) with the leading
garden care company in Europe and Oceania, EVERGREEN GARDEN CARE. The purpose
of this partnership is to evaluate the performance of Amoéba's biocontrol
products which, if successful, could lead to the development of a new range of
products for hobby gardeners.

Trials on new crops and new types of plants

Known for its consumer brands (KB, Substral, Fertilizer...), available in
specialist garden centers, DIY stores and online retailers, EVERGREEN GARDEN
CARE wants to test Amoéba's Willaertia magna C2c Maky amoeba lysate on
different diseases found in gardens and vegetable gardens.

Trials will include the following crops and plants:

- Potatoes (for late blight);

- Roses and other ornamentals (for rust and black spot).

Europe as a testing ground to meet the demands of individuals.

Through the program launched by EVERGREEN GARDEN CARE, the Amoéba lysate will
be tested in France, the United Kingdom, the Netherlands and Poland.

In France, the entry into force of the Labbé law compels local authorities
(since 1 January 2017) and private individuals (since 1 January 2019) to no
longer use or hold plant protection products, except for biocontrol products,
which are low-risk and authorized for organic agriculture. Amoéba's future
products, developed from the amoeba lysate, could be particularly suited to
this market in response to amateur gardeners' expectations and requirements for
natural treatment products with no environmental impact.

Amoéba and EVERGREEN GARDEN CARE are thus embarking on a targeted research
phase that could promote the commercial development of Amoéba's biocontrol
solutions for the general public.

"This new partnership illustrates the will to respond to the general public new
demands for high- performance and environmentally friendly solutions. Resulting
from 10 years of research and development, 100% organic, non-genetically
modified and targeting fungi, our Willaertia magna C2c Maky amoeba lysate is an
alternative response to the "all chemical" in our gardens and vegetable
gardens. These trials will make it possible to develop new formulations thus
broadening the spectrum of applications and, if they are conclusive, to offer
products to individuals that have already been tested on field crops, "
explains Fabrice Plasson, Chairman and CEO of Amoéba

Amoéba points out that the company is still in the testing phase for its
biocide and biocontrol applications and does not currently market any products.

About EVERGREEN GARDEN CARE
Evergreen Garden Care is the leading garden care company outside North America,
producing high quality garden care products designed to help people create
their own green oasis amid the rush of modern life. We believe in the beauty of
a green space - or oasis - whether it's a garden, balcony or potted plants
indoors, and we want to inspire anyone, anywhere, to make it easier to create
and maintain their own.

Founded in 2017 through the exclusive acquisition of the international
operations of Scotts Miracle-Gro, Evergreen Garden Care is a team of 800
passionate people whose primary mission is to help all levels gardeners to
maintain their lawns, grow fruits and vegetables to make their own green oasis
as beautiful as possible. With market-leading brands such as Miracle-Gro,
Fertilizer, Substral and Pokon in all the markets where we operate, we offer a
full range of products to gardeners in the UK, France, Belgium, the
Netherlands, Germany, Austria, Poland, the Nordic countries, Australia and New
Zealand. Our aim is to develop the best known brands and launch the most
exciting and relevant innovations for the consumer as we develop our new
company.

About AMOÉBA :

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
      MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
     Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:
Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 25, 2019 under number D19-0383 and the
prospectus approved by the AMF on january 16, 2020 under number 20-011 (a copy
of which is available on www.amoeba-biocide.com). The forward-looking
statements contained in this press release are also subject to risks not yet
known to AMOEBA or not currently considered material by AMOEBA. The occurrence
of all or part of such risks could cause actual results, financial conditions,
performance or achievements of AMOEBA to be materially different from such
forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - Amoéba: AMOEBA BIOCONTROL SOLUTIONS TESTED BY EVERGREEN GARDEN CARE FOR HOME GARDEN APPLICATIONS

Transparency directive : regulatory news

AMOEBA's latest news

Other stories